Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current concepts in biomarker technology for bladder cancers.

M Burchardt1, T Burchardt, A Shabsigh

  • 1Department of Urology, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.

Clinical Chemistry
|May 5, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study.

ESMO open·2023
Same author

[Early detection of prostate cancer: Towards a new paradigm?]

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

[High risk localized and locally advanced prostate cancer: Long-term oncological outcomes after prostatectomy].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022
Same author

Robotic-assisted laparoscopy living donor nephrectomy: Technique and results of a monocentric retrospective series.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022
Same author

[Assessment of positive surgical margins in the management of patients after radical prostatectomy for pT2 prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022

Emerging biomarkers show promise for detecting bladder cancer (transitional cell carcinoma, TCC) with higher accuracy than current methods. Further research is needed to develop reliable, noninvasive tests for improved patient monitoring.

Area of Science:

  • Urology
  • Oncology
  • Biomarker Discovery

Background:

  • Transitional cell carcinoma (TCC) of the bladder is a common malignancy with high recurrence rates.
  • Current diagnostic methods like urinalysis, cystoscopy, and cytology are invasive or lack sufficient sensitivity and specificity.
  • A noninvasive, reliable test is needed for improved detection and monitoring of TCC.

Purpose of the Study:

  • To review potential biomarkers for transitional cell carcinoma (TCC) of the bladder.
  • To assess the sensitivity and specificity of candidate biomarkers compared to existing diagnostic methods.

Main Methods:

  • Comprehensive literature search of Medline from 1980 to 1999.
  • Screening articles for potential TCC biomarkers with high sensitivity/specificity and correlation with diagnosis/staging.

Related Experiment Videos

  • Inclusion of extensively investigated compounds.

    • Main Results:

    • Several candidate biomarkers show significantly higher sensitivity (54-100%) and specificity (61-97%) than urinalysis and cytology (20-40% and 90%).
    • Biomarkers include nuclear matrix protein, fibrin/fibrinogen product, bladder tumor antigen, and others.
    • These biomarkers show potential for disease progression and prognosis assessment.

    Conclusions:

    • Candidate biomarkers are emerging for TCC detection and monitoring.
    • Further research, improved diagnostic techniques, and standardized interpretation are crucial for developing reliable biomarkers.
    • Adjuvant use of current biomarkers may enhance the diagnosis and monitoring of bladder cancer.